Livzon Pharmaceutical Group Inc
SZSE:000513
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (2.8), the stock would be worth ¥36.56 (12% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.5 | ¥32.65 |
0%
|
| 3-Year Average | 2.8 | ¥36.56 |
+12%
|
| 5-Year Average | 2.8 | ¥36.64 |
+12%
|
| Industry Average | 3.9 | ¥52.13 |
+60%
|
| Country Average | 2.8 | ¥36.62 |
+12%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
¥28.9B
|
/ |
Apr 2026
¥11.7B
|
= |
|
|
¥28.9B
|
/ |
Dec 2026
¥12.5B
|
= |
|
|
¥28.9B
|
/ |
Dec 2027
¥13.2B
|
= |
|
|
¥28.9B
|
/ |
Dec 2028
¥14B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Livzon Pharmaceutical Group Inc
SZSE:000513
|
29B CNY | 2.5 | 14.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
908.9B USD | 12.6 | 36 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 5.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 4.7 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 5 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 4.2 | 31.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 4 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 2.4 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD | 407.7 | 4 516.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.8 |
| 70th Percentile | 5.4 |
| Max | 5 034 353.9 |
Other Multiples
Livzon Pharmaceutical Group Inc
Glance View
Nestled within the bustling pharmaceutical landscape of China, Livzon Pharmaceutical Group Inc. has meticulously carved its path since its inception in 1985, blossoming into a formidable player in the industry. Based in Zhuhai, Guangdong Province, the company has steadily built a diversified portfolio across the pharmaceutical spectrum, focusing on both traditional Chinese medicine and modern biopharmaceutical products. Livzon leverages its robust research and development (R&D) capabilities to produce an extensive range of medications, catering primarily to major therapeutic areas such as cardiovascular, gastrointestinal, anti-infective, and oncology segments. With rigorous standards driving their production lines, they ensure premium quality, which has bolstered their reputation and allowed them to secure numerous patents and proprietary products. Livzon's revenue engine is fueled by its strategic blend of manufacturing prowess and a well-tuned distribution network. The company operates a comprehensive production chain, from raw material sourcing and pharmaceuticals manufacturing to extensive distribution channels stretching across domestic and global markets. It sustains strong collaborations with hospitals, medical institutions, and pharmacies, which facilitate widespread accessibility and market penetration. Additionally, Livzon invests heavily in innovation, aligning with global health demands through strategic partnerships and joint ventures, further pushing the boundaries of research. By balancing traditional medicinal wisdom with cutting-edge technologies, Livzon positions itself as an agile competitor in the ever-evolving pharmaceutical arena, continuously driving value creation and securing its foothold in the global marketplace.